09989.HK
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 4.23
−0.59%Aug 28, 2026, 08:42 UTC
Hepalink announced its H1 2026 results: revenue of 2.58 billion yuan, down 8.44% year-on-year; net profit attributable to shareholders of 275 million yuan, down 34.74% year-on-year; non-GAAP net profit of 162 million yuan, down 62.01% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.
Source: